Altimmune enters $200M ATM equity distribution agreement with Leerink Partners; terminates prior $150M ATM

Altimmune, Inc.

Entered November 2025 Agreement with Leerink Partners for ATM offering of up to $200M common stock.
Sales agent Leerink receives 3% commission on gross proceeds of shares sold under the program.
Prior February 2025 ATM program (up to $150M) terminated effective November 6, 2025 without penalties.
Shares sold through Nasdaq Global Market under Rule 415(a)(4) at the company's discretion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.